Myelodysplastic Syndromes: Insights on Diagnosis, Risk Assessment, and Treatment Approaches for 2026

1

MDS is a heterogeneous group of myeloid malignancies with a prevalence of 3 to 4 per 105 in the US, increasing with age.
2

Diagnosis of MDS is confirmed through bone marrow aspiration and biopsy, revealing dysplasia and cellular characteristics.
3

Risk assessment in MDS utilizes scoring systems like IPSS and IPSS-R, categorizing patients into lower and higher risk groups.
4

Cytogenetic analysis is crucial for prognosis and treatment decisions in MDS, with patterns evolving and impacting survival.
5

Diagnostic discrepancies in MDS can occur in 20% of patients, particularly in those with minimal dysplasia, affecting treatment.

American Journal Of Hematology

1